Trial intelligence / Profile preview

Imiquimod 5% Cream for Large/Multiple sBCC

NCT00189280Phase 3Completed

Sponsor
Meda
Start
May 2003
Primary completion
Oct 2007
Modality
Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
Countries
1
01

Overview

A Phase 3 trial of imiquimod in basal cell carcinoma (BCC), sponsored by Meda. Started May 2003; status: completed.

02

Drugs

imiquimod
03

Conditions

basal cell carcinoma (BCC)

Beyond the preview

Go deeper on NCT00189280.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00189280.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call